Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.39 |
| ▸ | USP2 | O75604 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11351132 | 0.84 | CYP2D6 (0.41) | CYP2D6USP2TSHRCYP3A4CYP2C9 | |
| SCHEMBL346839 | 0.84 | — | — | |
| SCHEMBL20160644 | 0.84 | CYP2D6 (0.41) | CYP2D6USP2TSHRCYP3A4CYP2C9 | |
| SCHEMBL1627509 | 0.83 | TSHR (0.35) | TSHR | |
| SCHEMBL670988 | 0.83 | TSHR (0.33) | CYP2D6USP2TSHRCYP3A4CYP2C9 | |
| Bromide SCHEMBL2686491 | 0.81 | — | — | |
| SCHEMBL30637307 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL2855605 | 0.81 | — | — | |
| SCHEMBL4798391 | 0.80 | — | — | |
| SCHEMBL28658 | 0.80 | CYP2D6 (0.42) | CYP2D6USP2TSHRCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192588-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2023-06-14 | — | — | EP | claimed |
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-02 | — | — | US | claimed |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-14 | — | — | US | claimed |
| EP-2970217-B1 | NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-09 | — | — | EP | claimed |
| US-9637473-B2 | Acrylamide derivatives as antimalarial agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-05-02 | — | — | US | claimed |
| US-20160024050-A1 | NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-01-28 | — | — | US | claimed |
| EP-2970217-A1 | NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2016-01-20 | — | — | EP | claimed |
| WO-2014141175-A1 | NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-09-18 | — | — | WO | claimed |
| EP-2448926-A1 | FLAVIN DERIVATIVES | Biorelix, Inc. (US) | 2012-05-09 | — | — | EP | claimed |
| EP-4192588-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2023-06-14 | — | — | EP | disclosed |
| CN-113149990-A | Siderophore-dihydrofolate reductase inhibitor conjugate and application thereof | 嘉圣生物医药(嘉兴)有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3347097-B1 | SUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF THE KINASES JAK, FLT3 AND AURORA | SUNSHINE LAKE PHARMA CO LTD (CN) | 2021-02-24 | — | — | EP | disclosed |
| EP-3312164-B1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES LLC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3327006-B1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES LLC (US) | 2020-05-20 | — | — | EP | disclosed |
| US-7517996-B2 | Azole compound | AJINOMOTO CO., INC. (JP) | 2009-04-14 | — | — | US | disclosed |
| EP-2007733-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007113596-A1 | AMIDE SUBSTITUTED INDAZOLE AND BENZOTRIAZOLE DERIVATIVES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-10-11 | — | — | WO | disclosed |
| US-20060194789-A1 | Fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof | AJINOMOTO CO., INC. (JP) | 2006-08-31 | — | — | US | disclosed |
| US-20060194850-A1 | Novel azole compound | AJINOMOTO CO. INC (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1683798-A1 | NOVEL FUSED POLYCYCLIC COMPOUND HAVING HETEROCYCLE AND MEDICINAL USE THEREOF | Ajinomoto Co., Inc. (JP) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336701-B2 | Pyridin-2-one derivatives of formula (II) useful as EP3 receptor antagonists | PTGER3, PTGER1, PTGER2 | CYP2D6 258/4885USP2 3724/4885TSHR 568/4885 |
| US-20190047960-A1 | PYRIDIN-2-ONE DERIVATIVES OF FORMULA (II) USEFUL AS EP3 RECEPTOR ANTAGONISTS | PTGER3, PTGER1, PTGER2 | CYP2D6 258/4885USP2 3724/4885TSHR 568/4885 |
| US-20060194789-A1 | Fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof | SLC2A4, SLC2A3, SLC2A1 | CYP2D6 280/4885USP2 4679/4885TSHR 692/4885 |
| US-20060194850-A1 | Novel azole compound | LPAR1, LPAR2, LPAR3 | CYP2D6 2076/4885USP2 3686/4885TSHR 539/4885 |
| US-20160024050-A1 | NOVEL ACRYLAMIDE DERIVATIVES AS ANTIMALARIAL AGENTS | RECQL, ACR, ABCC3 | CYP2D6 248/4885USP2 1232/4885TSHR 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.